Skip to main content

Table 3 Comparisons of progression-free survival, time on treatment, and overall survival between patients with multiple metastases versus single metastasis by line of therapy

From: Clinical outcomes among HR+/HER2− metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US

Multiple metastases (Ref: single metastasis)

Progression-Free Survival

Time on Treatment

Overall Survival

HR

(95 % CI)

P-value 

HR

(95 % CI)

P-value

HR

(95 % CI)

P-value

Univariate analysis

 First-line

1.87

(1.32, 2.65)

<0.001*

1.79

(1.30, 2.47)

<0.001*

3.32

(1.88, 5.85)

<0.001*

 Second-line

2.01

(1.33, 3.03)

0.001*

1.83

(1.26, 2.65)

0.001*

3.29

(1.48, 7.33)

0.004*

 Third-line and above

2.33

(1.54, 3.53)

<0.001*

2.04

(1.37, 3.02)

<0.001*

1.93

(0.94, 3.95)

0.074

Multivariate-adjusted analysisa

 First-line

1.43

(0.99, 2.08)

0.059

1.20

(0.85, 1.69)

0.313

1.98

(1.08, 3.64)

0.028*

 Second-line

1.69

(1.10, 2.59)

0.017*

1.47

(0.99, 2.17)

0.055

2.41

(1.05, 5.52)

0.038*

 Third-line and above

1.57

(1.00, 2.46)

0.049*

1.38

(0.90, 2.11)

0.143

1.09

(0.50, 2.36)

0.832

  1. CCI Charlson Comorbidity Index, CI confidence interval, ECOG Eastern Cooperative Oncology Group; HR hazard ratio, mBC metastatic breast cancer, Ref reference
  2. * P < 0.05
  3. aThe model adjusted for the following variables: age, race, insurance type at mBC diagnosis, treatment type, mBC type, adjusted CCI, bone metastasis at index therapy initiation, ECOG performance status, prior chemotherapy for mBC, and months from the initiation of the last adjuvant endocrine therapy to mBC diagnosis
Back to article page

Experimental Hematology & Oncology

ISSN: 2162-3619

Contact us